Modified P8 treatment for Alzheimer's disease
EARLY CLINICAL DEVELOPMENT OF MODIFIED P8 FOR THE TREATMENT OF ALZHEIMER'S DISEASE
['FUNDING_SBIR_2'] · CENNA BIOSCIENCES, INC. · NIH-11195113
A new modified P8 drug aims to lower toxic amyloid-beta in older adults with Alzheimer's disease to help protect memory and thinking.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CENNA BIOSCIENCES, INC. (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-11195113 on ClinicalTrials.gov |
What this research studies
You would be offered an experimental drug called modified P8 designed to reduce buildup of amyloid-beta in the brain. The company is moving this compound into early human testing to check safety, dosing, and how it affects amyloid and cognition. Study visits would likely include brain imaging, blood tests, and memory and function testing to track effects and side effects. If you join, you would come to the clinic for dosing and regular follow-up over the study period.
Who could benefit from this research
Good fit: Older adults (typically 65 years and older) with early-stage Alzheimer's disease or mild cognitive impairment due to Alzheimer's who meet the study's medical criteria would be the ideal candidates.
Not a fit: People with advanced Alzheimer's, non‑Alzheimer's dementias, or who cannot undergo study procedures are unlikely to receive benefit from this trial.
Why it matters
Potential benefit: If successful, this treatment could slow cognitive decline by lowering amyloid-beta with a potentially safer and more convenient option than current antibody therapies.
How similar studies have performed: Monoclonal antibodies that lower amyloid have shown modest to moderate cognitive benefits in trials, while peptide/small-molecule approaches like modified P8 are newer and less tested in humans.
Where this research is happening
LA JOLLA, UNITED STATES
- CENNA BIOSCIENCES, INC. — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DEWJI, NAZNEEN N — CENNA BIOSCIENCES, INC.
- Study coordinator: DEWJI, NAZNEEN N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.